From: Stochastic cost-effectiveness analysis on population benefits
Cost | Var_of_Cost | QALY | Var_of_QALY | \(\rho_{QC}\) | ||||
---|---|---|---|---|---|---|---|---|
LMWH | 21,512.00 | 41,648,952.96 | 0.53 | 28.09 | 0.1 | |||
Apixaban | 1,944.00 | 340,122.24 | 0.55 | 30.25 | 0.1 | |||
Rivaroxaban | 2,122.00 | 405,259.56 | 0.53 | 28.09 | 0.1 | |||
Edoxaban | 1,968.00 | 348,572.16 | 0.52 | 27.04 | 0.1 |
\(\rho_C\) | \(\rho_Q\) | |||||||
---|---|---|---|---|---|---|---|---|
LMWH | Apixaban | Rivaroxaban | Edoxaban | LMWH | Apixaban | Rivaroxaban | Edoxaban | |
LMWH | 1 | 0.005 | 0.005 | 0.005 | 1 | 0.005 | 0.005 | 0.005 |
Apixaban | 0.005 | 1 | 0.02 | 0.02 | 0.005 | 1 | 0.02 | 0.02 |
Rivaroxaban | 0.005 | 0.02 | 1 | 0.02 | 0.005 | 0.02 | 1 | 0.02 |
Edoxaban | 0.005 | 0.02 | 0.02 | 1 | 0.005 | 0.02 | 0.02 | 1 |